



cancers



an Open Access Journal by MDPI

Immune-Related Adverse Events in Patients with Cancer: From Bench to Bedside

Guest Editors:

Dr. Konstantinos Syrigos

Third Department of Internal
Medicine, Sotiria Hospital,
National and Kapodistrian
University of Athens, 11527
Athens, Greece

Dr. Ioannis Vathiotis

Third Department of Internal
Medicine, Sotiria Hospital,
National and Kapodistrian
University of Athens, 11527
Athens, Greece

Dr. Nikolaos K. Syrigos

Breast Oncology Center –
Translational Hub, Dana-
Farber/Harvard Cancer Center,
Boston, MA 02215, USA

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editors

Dear Colleagues,

Although there is growing consensus regarding the management of irAEs in cancer, more work is required to elucidate their exact mechanism of action, identify predictive biomarkers, and understand the mechanisms of steroid resistance with direct therapeutic implications.

Hosting perspectives from distinct subspecialties involved in preclinical as well as clinical research on irAEs, this Special Issue aims to provide a comprehensive summary of current knowledge on immunotherapy toxicity in patients with cancer. We also aim to present cutting-edge research that will shed light on various aspects of this evolving field, including but not limited to pathophysiology, taxonomy, and association with immunotherapy outcomes. A better understanding of irAEs will facilitate collaboration among different subspecialties and ultimately improve the management of immunotherapy toxicity in patients with cancer. We invite you to submit your work, including original articles, expert reviews, and commentaries on this important subject.



mdpi.com/si/164998

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI